Under brand names like Ozempic and Wegovy, semaglutide-based medications have made a significant difference in treating type ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face a lower risk of cancer ...

The active ingredient in the HonXi patch is SMGT-GLP-1, a glucagon-like peptide-1 receptor agonist. This compound is known for its ability to stimulate insulin secretion, inhibit glucagon release, and ...

The analysis found that obesity-related cancer occurred in 150 of 3,178 surgery patients (5.76 cases per 1,000 person-years) and in 148 of 3,178 patients taking GLP-1s (5.64 cases per 1,000 person ...

Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32% of Australians classified as obese in 2022 and the cost of obesity ...

GLP-1 receptor agonists work by mimicking the hormone GLP-1 (glucagon-like peptide-1), which acts in the brain to promote feelings of fullness after eating. So it's plausible that these drugs are ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ...

While glucose-lowering therapies as a whole did not significantly reduce dementia risk, GLP-1 receptor agonists (GLP-1Ras) were linked to a 45% lower risk of dementia.

In 568 patients who underwent bariatric surgery, those who also used a GLP-1 receptor agonist during the preoperative and postoperative period experienced significantly greater weight loss -- a 33 ...